|
|
| Risk group according to the NCCN guidelines |
| |
|
| Entire population n = 751 | Very low N = 45 | Low N = 137 | p-value very low vs. low |
| Age mean (range) |
65.3 (46 - 81) |
64.2 (51 - 74) |
63.8 (47 - 78) | 0.69 |
| Age <65 | 330 (43.9) | 21 (46.7) | 74 (54.0) | 0.32 |
| PSA*, ng/ml mean (range) |
9.9 (1.1 - 89.0) |
5.4 (1.1 - 8.6) |
6.3 (3.0 - 10.0) | <0.05 |
| PSA density ng/ml/cc mean (range) |
0.32 (0.02 - 3.30) |
0.11 (0.05 - 0.15) |
0.22 (0.06 - 0.45) | - |
| Clinical T stage, n (%) T1c or T2a T2b or T2c T3 |
659 (88%) 84 (11%) 8 (1%) |
45 (100%) - - |
137 (100%) - - | - |
| Biopsy Gleason score, n (%) ≤6 7 ≥8 |
251 (34%) 328 (44%) 167 (22%) |
45 (100%) - - |
137 (100%) - - | - |
| No .of positive cores 1, 2 3, 4 5, 6 ≥7 |
363 230 86 71 |
45 - - - |
78 42 10 7 | - |
| Pathological stage, n (%) pT2 pT3a pT3b pN+ |
498 (66%) 181 (24%) 60 (8%) 12 (2%) |
40 (89%) 5 (11%) - - |
111 (81%) 25 (18%) - 1 (1%) | 0.43 |
| Positive surgical margins, n (%) | 308 (41%) | 11 (24%) | 49 (36%) | 0.16 |
| Gleason score ≤6 7 ≥8 |
118 (15.7%) 466 (62.1%) 167 (22.2%) |
23 (51.1%) 21 (46.7%) 1 (2.2%) |
43 (31.4%) 88 (64.2%) 6 (4.4%) | 0.017 for ≤6 |